Accustem Sciences (ACUT) Cash from Operations (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Cash from Operations of 374176.0 for Q1 2026, down 28.95% year-over-year from 526602.62 in Q1 2025, and down 1773.64% quarter-over-quarter from 22357.0 in Q4 2025.
Accustem Sciences (ACUT) Cash from Operations (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Cash from Operations for 5 consecutive years, with 374176.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 28.95% year-over-year to 374176.0; the TTM figure through Mar 2026 stood at 934383.0 (down 30.34% YoY), while the FY2025 annual figure was 850389.0, down 28.06% from the prior year.
- Cash from Operations slipped to 374176.0 in Q1 2026 per ACUT's latest filing, from 22357.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 371984.0 in Q1 2022 and bottomed at 1000491.0 in Q2 2022.
- Historically, Cash from Operations has averaged 312372.18 across 5 years, with a median of 295031.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 219.92% — and 2025, when it jumped 5300.24%.
- Accustem Sciences' Cash from Operations stood at 622261.0 in 2022, then surged by 52.59% to 295031.0 in 2023, then surged by 100.14% to 414.0 in 2024, then jumped by 5300.24% to 22357.0 in 2025, then tumbled by 1773.64% to 374176.0 in 2026.
- Business Quant data shows ACUT's Cash from Operations at 374176.0 in Q1 2026, 22357.0 in Q4 2025, and 604131.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 728.46 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | -248,850.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -374,176.00 |
| Mar 31, 2026 | -374,176.00 |
| Dec 31, 2025 | 22,357.00 |
| Dec 31, 2025 | 22,357.00 |
| Sep 30, 2025 | -604,131.00 |
| Sep 30, 2025 | -604,131.00 |
| Jun 30, 2025 | 21,567.00 |
| Jun 30, 2025 | 21,567.00 |
| Mar 31, 2025 | -290,182.00 |
| Mar 31, 2025 | -290,182.00 |
| Dec 31, 2024 | 414.00 |
| Dec 31, 2024 | 414.00 |
| Sep 30, 2024 | -217,947.00 |
| Sep 30, 2024 | -217,947.00 |
| Jun 30, 2024 | -209,182.00 |
| Jun 30, 2024 | -209,182.00 |
| Mar 31, 2024 | -237,351.00 |
| Mar 31, 2024 | -237,351.00 |
| Dec 31, 2023 | -295,031.00 |
| Dec 31, 2023 | -295,031.00 |